The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. That said, here are two value stocks with strong fundamentals and one best left ignored.
One Value Stock to Sell:
Diebold Nixdorf (DBD)
Forward P/E Ratio: 10.5x
With roots dating back to 1859 and a presence in over 100 countries, Diebold Nixdorf (NYSE: DBD) provides automated self-service technology, software, and services that help banks and retailers digitize their customer transactions.
Why Should You Sell DBD?
- Flat sales over the last five years suggest it must find different ways to grow during this cycle
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- Low free cash flow margin of -0.7% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
Diebold Nixdorf’s stock price of $67.88 implies a valuation ratio of 10.5x forward P/E. If you’re considering DBD for your portfolio, see our FREE research report to learn more.
Two Value Stocks to Watch:
ANI Pharmaceuticals (ANIP)
Forward P/E Ratio: 7.7x
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Do We Like ANIP?
- Impressive 34.7% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Earnings growth has massively outpaced its peers over the last five years as its EPS has compounded at 19.9% annually
- Free cash flow margin grew by 38.5 percentage points over the last five years, giving the company more chips to play with
At $73.25 per share, ANI Pharmaceuticals trades at 7.7x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
APA Corporation (APA)
Forward P/E Ratio: 9.7x
Operating in three continents with a history stretching back to 1954, APA Corporation (NASDAQ: APA) explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the U.S., Egypt, and the U.K. North Sea.
What Makes APA Stand Out?
- Annual revenue growth of 4.8% over the last ten years beat the sector average and underscores the unique value of its offerings
- Dominant market position is represented by its $8.37 billion in revenue and gives it fixed cost leverage when sales grow
- Highly-profitable operating model results in strong unit economics and a top-tier gross margin of 67.8%
APA Corporation is trading at $43.42 per share, or 9.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
